TY - JOUR
T1 - Endoluminal bariatric and metabolic therapies
T2 - State-of-the-art
AU - Bakheet, Nader
AU - Badurdeen, Dilhana
AU - Sartoretto, Adrian
AU - Kumbhari, Vivek
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Purpose of reviewThe aim of this review is to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoluminal bariatric and metabolic procedures.Recent findingsThe landscape of endoluminal devices and techniques for treating obesity has expanded significantly, with FDA-approved therapies currently available to patients with a body mass index values as high as 50 kg/m2. Although notable advancements have been made in this area, there is a need for further emphasis to be placed on the metabolic improvements resulting from these therapies, in addition to the conventional focus on weight loss outcomes. Some of these procedures are now FDA approved for the treatment of metabolic disease as opposed to weight loss. To achieve the most favorable results, it is imperative that all endoluminal interventions are combined with a moderately intensive diet and lifestyle program lasting at least 12 months.SummaryEndoluminal metabolic and bariatric therapy represents a bridge between lifestyle counseling, pharmaceutical interventions, and the most efficacious treatment for obesity, bariatric surgery. By virtue of its minimally invasive approach, this therapy may be an appealing option for patients who are ineligible for, or averse to, bariatric surgery and who have experienced suboptimal outcomes or unable to afford medical treatments. Furthermore, these interventions may be particularly beneficial in the early stages of obesity.
AB - Purpose of reviewThe aim of this review is to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoluminal bariatric and metabolic procedures.Recent findingsThe landscape of endoluminal devices and techniques for treating obesity has expanded significantly, with FDA-approved therapies currently available to patients with a body mass index values as high as 50 kg/m2. Although notable advancements have been made in this area, there is a need for further emphasis to be placed on the metabolic improvements resulting from these therapies, in addition to the conventional focus on weight loss outcomes. Some of these procedures are now FDA approved for the treatment of metabolic disease as opposed to weight loss. To achieve the most favorable results, it is imperative that all endoluminal interventions are combined with a moderately intensive diet and lifestyle program lasting at least 12 months.SummaryEndoluminal metabolic and bariatric therapy represents a bridge between lifestyle counseling, pharmaceutical interventions, and the most efficacious treatment for obesity, bariatric surgery. By virtue of its minimally invasive approach, this therapy may be an appealing option for patients who are ineligible for, or averse to, bariatric surgery and who have experienced suboptimal outcomes or unable to afford medical treatments. Furthermore, these interventions may be particularly beneficial in the early stages of obesity.
KW - endoscopic sleeve gastroplasty
KW - gastrointestinal bypass sleeve
KW - gastroplasty
KW - intragastric balloon
UR - http://www.scopus.com/inward/record.url?scp=85166392799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166392799&partnerID=8YFLogxK
U2 - 10.1097/MOG.0000000000000967
DO - 10.1097/MOG.0000000000000967
M3 - Review article
C2 - 37522920
AN - SCOPUS:85166392799
SN - 0267-1379
VL - 39
SP - 362
EP - 369
JO - Current Opinion in Gastroenterology
JF - Current Opinion in Gastroenterology
IS - 5
ER -